secwatch.observer — SEC 8-K summary
======================================

Issuer:     Protagenic Therapeutics, Inc.new (PTIX)
CIK:        0001022899
Form:       8-K
Filed at:   2024-05-24T23:59:59+00:00
Accession:  0001493152-24-021383
Event type: regulatory
Sentiment:  negative
Materiality: 0.85
Item codes: 3.01
LLM model:  deepseek-v4-flash:cloud@v2

Protagenic Therapeutics receives Nasdaq deficiency notice for failing minimum equity requirement
--------------------------------------------------------------------------------

- Company's stockholders' equity fell below Nasdaq's $2.5M minimum as of March 31, 2024.
- Must submit a compliance plan by July 8, 2024; Nasdaq may grant up to 180-day extension.
- If plan rejected, common stock (PTIX) faces potential delisting; no immediate effect.
- Company exploring collaborations and capital raising to regain compliance.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224021383/0001493152-24-021383-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1022899/000149315224021383/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-24-021383

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer